Disease severity is not predictive of the dose required for apomorphine sublingual film (APL-130277) to convert a patient with Parkinson’s disease from OFF to fully ON
Objective: Evaluate whether baseline disease severity is predictive of the effective APL-130277 dose to turn a patient with Parkinson's disease (PD) from OFF to fully…Oral apomorphine film (APL-130277) produces no buccal mucosal irritation: Results of a toxicological study
Objective: Determine the tolerance of and potential for cheek pouch buccal mucosa irritation following the administration of apomorphine film (APL-130277). Background: APL-130277 is a sublingual…APL-130277 is a sublingual film being studied in phase 3 trials to rapidly turn patients ON from OFF episodes by delivering apomorphine via the oral mucosa
Objective: Evaluate if any differences exist in the efficacy of APL-130277 doses to turn a patient with Parkinson's disease (PD) from OFF to fully ON…Pharmacokinetic-pharmacodynamic effects of apomorphine sublingual film (APL-130277) for the rapid management of OFF episodes in patients with Parkinson’s disease
Objective: Determine the pharmacokinetic/pharmacodynamic effects of APL-130277 on OFF episodes in patients with Parkinson's disease (PD). Background: APL-130277 is a sublingual film being studied in…Minimum MDS-UPDRS part III change needed to convert a Parkinson’s disease patient from the OFF to full ON state with apomorphine sublingual film (APL-130277)
Objective: Determine the minimum MDS-UPDRS Part III improvement needed to convert a patient from the morning OFF state to a full ON with APL-130277. Background:…PERFORM: Controlled study in fluctuating PD patients examining the effects of motor state on the outcomes resulting from a structured physical therapy (PT) program
Objective: To determine if outcomes following a PT program are improved if PT sessions are conducted while PD patients are in an on motor state…Subcutaneous apomorphine reduces OFF time and dyskinesias and improves quality of life in Parkinson’s disease (PD) – 5-year follow-up of patients in Greece
Objective: To evaluate the long-term efficacy of subcutaneous apomorphine (APO) injection and APO infusion in controlling motor fluctuations and dyskinesias and the impact on quality…
- « Previous Page
- 1
- …
- 11
- 12
- 13